Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Doeltreffendheid van een korte interventie om de geestelijke gezondheid van seksuele en genderminderheden te verbeteren: gerandomiseerde gecontroleerde studie. (ESCREVA-SE)

Doeltreffendheid van een korte, zelfgeleide, online schrijfinterventie om de geestelijke gezondheidsresultaten bij seksuele en genderminderheden te verbeteren: een gerandomiseerde gecontroleerde studie.

Experiences of violence, from micro to physical aggressions, have a deleterious impact on mental health. According to the Minority Stress Theory, unfavorable social conditions (such as anticipated and experienced discrimination and internalized homophobia), mediated by resilience strategies, can lead to mental health or illness. Sexual and gender minorities (SGM) face stigma and discrimination aggravating multiple aspects of their lives: from school drop-out to halting health care access. SGM reveal avoiding medical assistance for fear of discrimination while health professionals disclose feeling unprepared to handle SGM health needs. There are two main challenges: 1) developing specific psychological interventions to reduce the impact of stigma and discrimination on SGM' mental health; and 2) training public health professionals to properly address SGM needs. Therefore, the present trial aims to assess the efficacy of a brief, self-guided, on-line, asynchronous and unsupervised psychological intervention in improving SGM' mental health.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Werkelijk)

306

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brazilië, 90619-900
        • Pontifícia Universidade Católica do Rio Grande do Sul

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

16 jaar tot 100 jaar (Kind, Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Self-identity as sexual and gender minority.
  • Being older than 16 years old.
  • Have a stable on-line connection for, at least, 20 minutes in a place where won't be disturbed.
  • Reports, in the baseline survey, previous experiences of discrimination, having depression or anxiety symptoms.
  • Currently living in Rio Grande do Sul.

Exclusion Criteria:

  • Disagrees with the consent form.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verdrievoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Expressive writing

Participants will be invited to join three writing activities, lasting 20 minutes daily in D1, D3, and D5 of the same week. For example, to write about a difficult or painful experience related discrimination and their feelings about it.

Write, continuously for 20 minutes, about deepest emotions and thoughts concerning experiences of minority stress, exploring a particular event and how it has affected the participant.

Experimenteel: Self-affirmation

Aiming to build self-efficacy, participants will be invite to writing, during 20 minutes daily in D1, D3, and D5 of the same week, a letter to a sexual and gender minority peer suffering from stigma and discrimination.

Write, continuously for 20 minutes, about values the participant think is important to overcome experiences of minority stress.

Placebo-vergelijker: Placebo

Participants will be instruct to write about their daily routine, during 20 minutes daily in D1, D3, and D5 of the same week.

Write, continuously for 20 minutes, about their daily routine, without expressing feelings and deep thoughts about it.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change from baseline depression at 3 and 6 moths after the intervention.
Tijdsspanne: Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).

Assessed using the Center for Epidemiologic Studies - Depression (CES-D). CES-D is composed of 20 items. The final score ranges from 0 to 60 points. Originally, the cutoff point of the CES-D scale to identify the presence of depressive symptoms is equal or higher 16 points. However, when considering Brazilian samples, the cutoff point of equal or higher 12 points was proposed.

Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
Change from baseline anxiety at 1 week, and 3 and 6 moths after the intervention.
Tijdsspanne: Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).

Evaluated using the Generalized Anxiety Disorder 7-item (GAD-7). The GAD-7 consists of 7 questions based in part on the DSM-IV criteria for GAD and reflects the frequency of symptoms during the preceding 2-week period. The GAD-7 requires approximately 1-2 minutes to administer and for each symptom queried provides the following response options: "not at all," "several days," "over half the days" and "nearly every day" and these are scored, respectively, as 0, 1, 2 or 3. A score of 10 or greater on the GAD-7 represents a reasonable cut point for identifying cases of GAD.

Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
Change from baseline social phobia at 1 week, and 3 and 6 moths after the intervention.
Tijdsspanne: Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).

Evaluated using the Social Avoidance and Distress Scale (SADS). SADS is a 28 item true/false scale that measures measures aspects of social anxiety including distress, discomfort, fear and avoidance. A total score on the SADS is obtained based on the answers to the true/false questions. Higher scores indicate greater social anxiety.

Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
Change from baseline post-traumatic stress at 1 week, and 3 and 6 moths after the intervention.
Tijdsspanne: Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).

Post-Traumatic Stress Disorder Checklist - Civilian Version (PCL-C). The PCL-C is a 17-item self-report checklist of PTSD symptoms based closely on the DSM-IV criteria. The score consists in adding up all items from each of the 17 items for a total severity score (range = 17-85). The cut off 17-29 shows little to no severity, 28-29 suggests some PTSD symptom, 30-44 moderate to moderately high severity of PTSD symptoms, and 45-85 high severity of PTSD symptoms.

Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
Change from baseline on suicide ideation at 3 and 6 moths after the intervention.
Tijdsspanne: Baseline (T0), three months after the intervention (T2), and six the intervention (T3).

Patient Health Questionnaire-9 (PHQ-9). The PHQ-9 is a clinically-validated screening tool that healthcare providers use to screen for depression, and also to diagnose and monitor the severity of the condition. A PHQ-9 score total of 0-4 points equals "normal" or minimal depression. Scoring between 5-9 points indicates mild depression, 10-14 points indicates moderate depression, 15-19 points indicates moderately severe depression, and 20 or more points indicates severe depression.

Baseline (T0), three months after the intervention (T2), and six the intervention (T3).
Change from baseline on substance use at 3 and 6 moths after the intervention.
Tijdsspanne: Baseline (T0), three months after the intervention (T2), and six the intervention (T3).

Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) is an 8 questions tool that detects substance use and related problems. A 'global continuum of risk score' (or total substance involvement) is calculated by the addition of all items for all substances on the ASSIST and has a maximum score of 208.

Baseline (T0), three months after the intervention (T2), and six the intervention (T3).
Change from baseline on sex risk behaviors at 3 and 6 moths after the intervention.
Tijdsspanne: Baseline (T0), three months after the intervention (T2), and six the intervention (T3).

Inquired using yes-no questions concerning unprotected intercourse and multiple sex partners, as well as the Perceived Risk of HIV Scale. Perceived Risk of HIV Scale is a self-report 8-item measure developed to assess how people think and feel about their risk of HIV infection based on their previous sexual behavior and covering several dimensions of perceived HIV risk. Higher scores are associated with a greater number of sex partners, episodes of unprotected sex and having sex while high.

Baseline (T0), three months after the intervention (T2), and six the intervention (T3).

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change from baseline on resilience at 1 week, and 3 and 6 moths after the intervention.
Tijdsspanne: Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).

Wagnild and Youngs's Resilience Scale that has presented the following scoring for the total score: 25-100 = Very low, 101-115 = Low, 116-130 = On the low end, 131-145 = Moderate, 146-160 = Moderately high, and 161-175 = High.

Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).
Change from baseline on self-esteem at 1 week, and 3 and 6 moths after the intervention.
Tijdsspanne: Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).

Rosenberg Self-Esteem Scale. The scale ranges from 0-30. Scores between 15 and 25 are within normal range; scores below 15 suggest low self-esteem.

Baseline (T0), one week after the intervention (T1), three months after the intervention (T2), and six the intervention (T3).

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

15 augustus 2022

Primaire voltooiing (Werkelijk)

30 december 2022

Studie voltooiing (Werkelijk)

19 september 2026

Studieregistratiedata

Eerst ingediend

11 maart 2022

Eerst ingediend dat voldeed aan de QC-criteria

22 april 2022

Eerst geplaatst (Werkelijk)

27 april 2022

Updates van studierecords

Laatste update geplaatst (Werkelijk)

24 september 2026

Laatste update ingediend die voldeed aan QC-criteria

22 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren